What are the odds of dying from a smokeless-tobacco-related disease as a regular user?
Evidence quality 4.13/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 4/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 3/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 3/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 8.3
12% lifetime chance
Most people overestimate this.
range 1 in 20 to 1 in 4.0
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Smokeless tobacco — snus, chewing tobacco, moist snuff — occupies an ambiguous space in public health perception. Many users treat it as a substantially safer substitute for cigarettes, citing the absence of combustion and the absence of lung cancer as the defining differences. Others assume the risk is comparable to smoking, equating "tobacco" with "similar hazard." Neither picture is accurate. The evidence points to a genuine but considerably smaller mortality risk than cigarette smoking — roughly a quarter to a third of smoking's attributable burden — concentrated mainly in cardiovascular disease and, for products higher in tobacco-specific nitrosamines (TSNA), oral and esophageal cancer. The headline figure is not zero, and it is substantially lower than the ~50% lifetime attributable mortality for a lifelong cigarette smoker.
Rough estimate: Many users believe the risk is negligible; others assume it matches cigarette smoking
Source: editorial intuition, not polled
Actual
Roughly 1 in 8 lifelong regular smokeless tobacco users die from a tobacco-attributable disease
lifelong regular smokeless tobacco users (primarily snus-type products in Scandinavia; US chewing tobacco users may have lower absolute mortality based on contemporaneous US data)
Show derivation
Reference subgroup: an adult who begins regular smokeless tobacco use in early adulthood and continues for decades, modelled primarily on Swedish snus data (the highest-quality long-term cohort evidence available). The 0.12 point estimate derives from the following reasoning. Shafey et al. (PMC7825961), a pooled analysis of eight Swedish prospective cohort studies (N=169,103 never-smoking men; 10,928 deaths over 2,857,312 person-years), found current snus users had an all-cause mortality adjusted HR of 1.28 (95% CI 1.20–1.35) and a cardiovascular mortality HR of 1.27 (95% CI 1.15–1.41) relative to never-users of tobacco. The population attributable fraction implied by an HR of 1.28 is (HR-1)/HR = 0.28/1.28 ≈ 22%. Applying that attributable fraction to the total lifetime mortality of a cohort (which asymptotically approaches 1.0 over a long enough follow-up) yields an approximate lifetime attributable mortality probability of ~12–18%. The 0.12 central estimate deliberately sits at the lower end of this range because: (1) US studies using NLMS and NHIS nationally representative cohorts (Rostron et al. 2018, PMC6458834) found null all-cause mortality (HR ≈ 1.0) for exclusive smokeless tobacco users in US populations, suggesting product-class differences (US chewing tobacco and moist snuff contain higher TSNAs than Swedish pasteurized snus); (2) modern US oral cancer incidence in smokeless tobacco users is only modestly elevated over non-users in the JMIR Cancer 2024 population-based study (HR 1.4, barely significant); (3) the Swedish pooled data represent heavy long-term male snus users who are older on average than US SLT users. Uncertainty range 0.05–0.25 reflects the genuine evidence conflict between Swedish cohort mortality data and US null-finding cohort data. Scope is declared subgroup_lifetime because this is a per-regular-user probability, not a general-population lifetime risk, and is not directly comparable to per-US-adult figures on other Likelier pages.
Caveats: This entry is anchored on Swedish snus cohort data, which provides the largest a…
This entry is anchored on Swedish snus cohort data, which provides the largest and most methodologically rigorous long-term mortality evidence. US cohort data (NLMS and NHIS) found null all-cause mortality for exclusive SLT users, which produces the wide uncertainty range (0.05–0.25). The discrepancy likely reflects product differences (Swedish snus is pasteurized with lower TSNA content than most US chewing tobacco and moist snuff), cohort composition, and follow-up duration differences. The headline 0.12 is an intermediate estimate designed to represent a typical long-term regular user of Western smokeless tobacco products, weighted toward the Swedish data as the longer-follow-up source, with downward adjustment for the US null findings. South and Southeast Asian smokeless tobacco products (gutkha, pan masala, betel quid with tobacco) carry substantially higher cancer risks and are in a different risk category entirely; this entry does not apply to those products. The oral cancer channel for modern US SLT users (primarily moist snuff) is substantially weaker than older literature suggested — contemporary incidence data show near-identical rates in SLT users and never-tobacco users. The primary remaining pathway is cardiovascular, particularly fatal myocardial infarction and heart failure in existing-CVD patients.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Inheriting AUD risk
If a parent had alcohol use disorder, what are the odds you'll develop alcohol use disorder yourself?
Compulsive sexual behavior
What are the odds of developing compulsive sexual behavior disorder?
Chronic painkillers
What are the odds of being harmed by taking over-the-counter painkillers regularly?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The best available long-term evidence suggests that roughly 1 in 8 lifelong regular smokeless tobacco users will die from a tobacco-attributable disease — a figure that is substantially lower than the roughly 1 in 2 lifetime attributable mortality for cigarette smokers, yet clearly above zero. That estimate comes primarily from a pooled analysis of eight Swedish prospective cohort studies (Shafey et al. 2021, N=169,103 never-smoking men; 10,928 deaths), which found current snus users had an all-cause mortality adjusted hazard ratio of 1.28 (95% CI 1.20–1.35) and a cardiovascular mortality HR of 1.27 (1.15–1.41) compared to never-tobacco users. The attribution fraction implied by HR 1.28 is approximately 22% of deaths in the exposed cohort. An important qualifier: US nationally representative cohort studies (Rostron et al. 2019; NLMS and NHIS datasets) found essentially null all-cause mortality for exclusive US smokeless tobacco users, raising the real possibility that product formulation — Swedish pasteurized snus versus fermented US chewing tobacco and moist snuff — is the variable driving the Swedish-US divergence.
The oral cancer channel, historically the centrepiece of the smokeless-tobacco-health narrative, is now considerably weaker than it appeared in studies from the 1980s and 1990s. A 2024 population-based study of 19,536 US oral cancer cases (JMIR Cancer) found that exclusive smokeless tobacco users and never-tobacco users had nearly identical absolute oral cancer incidence rates — 20.6 versus 22.1 per 100,000 person-years — with only a borderline-significant relative risk of 1.4. This reflects the product shift away from dry snuff (the highest tobacco-specific nitrosamine product) toward moist snuff, which now accounts for roughly 80% of the US market. Older meta-analyses finding oral cancer relative risks of 2.6 to 4.7 for US smokeless tobacco were predominantly capturing dry-snuff users and South and Southeast Asian product users (where gutkha and betel quid products carry order- of-magnitude higher cancer risks). The cardiovascular pathway — primarily via nicotine-driven sympathetic activation, elevated blood pressure, and heart rate effects — is now the primary biological route through which the modest Swedish mortality excess likely operates, and is the mechanism most consistently supported across study populations.
The wide uncertainty band on this entry (0.05–0.25) is not a presentation failure but an accurate reflection of genuine evidence conflict. The Swedish data point to a meaningful absolute mortality elevation; the US data largely do not. Reconciling that conflict requires resolving questions about product formulation, follow-up length, background population health, and residual confounding by socioeconomic status — none of which have been fully resolved in the literature. What is clear from the data is what the entry is framed as: the risk is not zero, it is not equivalent to cigarette smoking, and the magnitude depends substantially on what specific product a user is consuming and whether they have pre-existing cardiovascular disease.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] BMJ Open (Shafey et al.) — Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies
Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies- Statistic
Current snus users: all-cause mortality aHR 1.28 (95% CI 1.20–1.35); cardiovascular mortality aHR 1.27 (1.15–1.41)- Excerpt
“"Current snus users had an increased risk of all-cause mortality (aHR 1.28, 95% CI 1.20 to 1.35), cardiovascular mortality (aHR 1.27, 95% CI 1.15 to 1.41), cancer mortality (aHR 1.12, 95% CI 1.00 to 1.26) and other cause mortality (aHR 1.37, 95% CI 1.24 to 1.52) compared with never-users of tobacco. Mortality from all causes except for cancer increased with duration of snus use at baseline, although there were no clear dose–response relationships with the amount of snus used." ”
- Source data from
- 2021-01-27
- Accessed
- 2026-05-22 · archived copy
- Calculation
- This pooled analysis of 169,103 never-smoking Swedish men provides the primary quantitative basis for the mortality hazard estimate. The HR 1.28 all-cause figure is the main anchor. Attributable fraction = (1.28-1)/1.28 = 0.219; applied to lifetime mortality (approaching 1.0 over a full adult lifespan) yields ~22% attributable in theory; adjusted to ~12% central estimate to account for US data showing null findings (see Rostron et al.). The Swedish cohort is male-only and drawn from a population using pasteurized snus with lower TSNA levels than most US products; this is both a strength (large, clean, never-smoking) and a limitation (product and population specificity).
- Independence
- This is the largest and most methodologically rigorous source for snus-specific mortality. It is independent from the Rostron US cohort study below. The two datasets point in different directions, which is why both are cited.
-
[2] Tobacco Control (Rostron et al.) — Smokeless tobacco mortality risks: an analysis of two contemporary nationally representative longitudinal mortality studies
Smokeless tobacco mortality risks: an analysis of two contemporary nationally representative longitudinal mortality studies- Statistic
Exclusive SLT users in US: all-cause mortality HR ≈ 1.0 in both NLMS and NHIS cohorts; no evidence of excess cancer mortality- Excerpt
“"No evidence of excess mortality risk among exclusive SLT users was found in either study. [...] Heart failure: NHIS HR 2.75 (95% CI 1.55–4.89). [...] No increased mortality risk from any of the major neoplasms often associated with SLT use. [...] Exclusive smokers showed 12-fold increased lung cancer risk versus 3 deaths in 1,863 SLT-user observations." ”
- Source data from
- 2019-04-01
- Accessed
- 2026-05-22 · archived copy
- Calculation
- Rostron et al. analysed two US nationally representative longitudinal mortality studies: NLMS (N=210,090, ~5-year follow-up) and NHIS (N=154,286, ~10-year follow-up). Among exclusive SLT users, all-cause mortality HR was approximately 1.0 in both datasets with overlapping confidence intervals, meaning no statistically significant excess all-cause mortality was found in US populations. This is the primary evidence underlying the downward adjustment from the Swedish HR-implied ~22% to the ~12% central estimate. The notable exception is heart failure (HR 2.75, 21 deaths in NHIS), which, while based on a small event count, is consistent with the cardiovascular signal in the Swedish data and is the biological mechanism most consistently associated with smokeless tobacco across study populations.
- Independence
- Rostron et al. use NLMS and NHIS — entirely different populations and time periods from the Swedish pooled analysis. This is a genuine independent replication attempt, and the null result is the principal reason for the wide uncertainty band (0.05–0.25) on this entry.
-
[3] JMIR Cancer — Oral Cancer Incidence Among Adult Males With Current or Former Use of Cigarettes or Smokeless Tobacco: Population-Based Study
Oral Cancer Incidence Among Adult Males With Current or Former Use of Cigarettes or Smokeless Tobacco: Population-Based Study- Statistic
ST-only users: oral cancer incidence 20.6 per 100,000 vs never-user 22.1 per 100,000; modest HR 1.4 (95% CI 1.1–1.9) for exclusive ST vs never-tobacco- Excerpt
“"Never Cig/Current ST (smokeless tobacco users): 20.6 per 100,000 (95% CI 18.3–23.3). Never Cig/Never ST (non-users): 22.1 per 100,000 (95% CI 21.5–22.6). [...] smokeless tobacco users had 1.4 times higher oral cancer risk compared to never users (95% CI 1.1–1.9, P=.02). [...] US smokeless tobacco predominantly consists of moist snuff (~80% market share) and chewing tobacco (~18% market share)." ”
- Source data from
- 2024-01-15
- Accessed
- 2026-05-22 · archived copy
- Calculation
- This 2024 population-based study of 19,536 US oral cancer cases is the most current direct evidence on oral cancer incidence for US SLT users. The absolute incidence rates are nearly identical between ST users (20.6) and never-tobacco users (22.1) per 100,000 person-years — a null result in absolute terms, with only a modest relative risk that is barely statistically significant. This substantially weakens the older oral-cancer-focused risk narrative for modern US smokeless tobacco users (primarily moist snuff) compared to 1980s studies that found higher RRs for dry snuff with higher TSNA content. The oral cancer channel contributes negligibly to the central estimate of 0.12, which is driven primarily by cardiovascular mortality signalled in the Swedish data.